This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Can Phosphate Binders Drive DaVita Stock Before Q2 Earnings?
by Zacks Equity Research
DVA rides early momentum from phosphate binders ahead of second-quarter 2025 earnings, but PD supply issues may cloud growth.
Should Value Investors Buy Aveanna Healthcare (AVAH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Medical Stocks Lagging Aveanna Healthcare (AVAH) This Year?
by Zacks Equity Research
Here is how Aveanna Healthcare (AVAH) and HCA Healthcare (HCA) have performed compared to their sector so far this year.
Encompass Health Corporation (EHC) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Encompass Health (EHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Encompass Health to Expand Florida Presence With New 50-bed Facility
by Zacks Equity Research
EHC already boasts a massive footprint of 167 hospitals in 38 states and Puerto Rico.
Here Is Why Bargain Hunters Would Love Fast-paced Mover Aveanna (AVAH)
by Zacks Equity Research
Aveanna (AVAH) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Pediatrix Medical's Q1 Earnings Beat Estimates on Declining Costs
by Zacks Equity Research
MD anticipates adjusted EBITDA to be between $220 million and $240 million in 2025.
Select Medical Lags Q1 Earnings Estimates, Lowers Revenue Outlook
by Zacks Equity Research
SEM reiterates that earnings for 2025 are likely to be between $1.09 and $1.19 per share.
Can Revenue Cycle Operations Drive DVA Stock Before Q1 Earnings?
by Zacks Equity Research
Continued strength in revenue cycle operations is likely to have boosted DaVita's top line in the first quarter despite supply challenges weighing on its performance.
TDOC Q1 Loss Narrower Than Estimates on Strong Integrated Care Unit
by Zacks Equity Research
Teladoc Health expects Integrated Care members to be between 101 million and 103 million in 2025.
Compared to Estimates, Aveanna (AVAH) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Aveanna (AVAH) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
The Pennant Group, Inc. (PNTG) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
The Pennant Group (PNTG) delivered earnings and revenue surprises of 22.73% and 3.68%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
MTD Q1 Earnings Top Estimates, Sales Decline Y/Y, Shares Rise
by Zacks Equity Research
Mettler-Toledo International's Q1 results reflect growth in the Laboratory business, a decline in Industrial, and continued weakness in the Food Retail segment.
Cigna Q1 Earnings Beat Estimates on Evernorth Health Strength
by Zacks Equity Research
CI increases adjusted earnings guidance for 2025 to $29.60 per share from the previous estimate of $29.50.
Community Health Q1 Earnings Top on Rising Patient Volumes, Stock Up 8%
by Zacks Equity Research
CYH continues to witness growth in same-store admissions in the first quarter. Net loss per share is expected between 55 cents and breakeven in 2025.
Universal Health Q1 Earnings Beat on Strong Acute Care Admissions
by Zacks Equity Research
UHS continues to witness growth in acute care facilities' patient days, while behavioral health care services witness decline.
Option Care (OPCH) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Option Care (OPCH) delivered earnings and revenue surprises of 11.11% and 5.38%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
HCA Healthcare Q1 Earnings Beat on Growing Patient Volumes
by Zacks Equity Research
HCA continues to witness growth in reported and same-facility admissions. The company reaffirms 2025 guidance.
4 Cheap Stocks With Solid Fundamentals to Offset Market Uncertainty
by Indrajit Bandyopadhyay
Here we discuss four stocks with strong fundamentals with attractive valuation following recent decline. These are AVAH, CALM, COMM and STRL.
Molina Healthcare Q1 Earnings Beat Estimates on Growing Premiums
by Zacks Equity Research
MOH continues to expect 2025 premium revenues to be around $42 billion.
Elevance Health's Q1 Earnings Beat Estimates on Rising Premiums
by Zacks Equity Research
ELV continues to witness significant growth in Q1 revenues. However, its operating costs surge.
UnitedHealth Lags Q1 Earnings & Revenues, Slashes Estimates
by Zacks Equity Research
UNH continues to witness significant growth in medical costs. However, its operating cost ratio improves.
CYH to Sell Stake in Cedar Park Regional to Ascension in $460M Deal
by Zacks Equity Research
Community Health is set to divest an 80% ownership stake in Cedar Park Regional to Ascension Health.
Centene Extends SilverSummit's Presence to the Edges of Nevada
by Zacks Equity Research
CNC's subsidiary, SilverSummit, secures a five-year Nevada Medicaid contract, reinforcing its foothold in managed care in rural and frontier areas.
LifeStance Health (LFST) Surges 5.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
LifeStance Health (LFST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.